Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Early treatment with semaglutide, before the menopause transition begins, could lead to additional weight loss

  60% confidence

• New clinical and real-world data demonstrate that effective weight management with semaglutide around menopause addresses medical complications of obesity such as heart disease and metabolic dysfunction, as well as daily burdens such as migraine, depression and menopause-related challenges

  60% confidence

• In SELECT trial post-hoc analysis, perimenopausal women with obesity and heart disease had a 42% lower cardiovascular risk on semaglutide vs placebo; postmenopausal women had 13% lower risk. The difference between groups was not statistically significant.

  60% confidence

• An estimated 450 million women worldwide experience menopause or perimenopause symptoms, with roughly 80% reporting that menopause interferes with their lives and one-third experiencing depression during this transition

  60% confidence

• Cardiovascular disease remains the leading cause of death in women worldwide, claiming more lives than all cancers combined. Women's cardiovascular symptoms are frequently dismissed or misdiagnosed, and women remain underrepresented in heart disease research.

  60% confidence

• During menopause years, women's risk of heart attack rises notably to the same level as men's cardiovascular risk

  60% confidence

• In a US real-world study, women taking Wegovy alone had 42–45% lower risk of migraine starting six months after initiation and 25% lower risk of depression, compared with those taking menopausal hormone therapy alone

  60% confidence

• Obesity affects approximately 504 million women worldwide — nearly 1 in 5 women globally — and is associated with increased risk of cardiovascular disease, type 2 diabetes, certain cancers, osteoarthritis, sleep apnoea and mental health disorders

  60% confidence

• Perimenopausal and postmenopausal women achieved weight loss of 19.7% and 19.8% respectively with semaglutide 7.2 mg at 72 weeks in the STEP UP trial

  60% confidence

• Premenopausal women with obesity lost an average of 22.6% of their body weight on once-weekly semaglutide 7.2 mg, with 41.4% achieving 25% or more weight loss, compared with placebo in the STEP UP trial

  60% confidence

• Whether looking at cardiovascular outcomes or weight loss across menopausal stages, semaglutide appears to offer meaningful benefits for women with obesity that extend well beyond weight loss alone

  60% confidence

• Average waist circumference reduction at 72 weeks was 17.5% in premenopausal, 15.6% in perimenopausal, and 15.3% in postmenopausal women taking semaglutide 7.2 mg in the STEP UP trial, indicating major loss of visceral fat

  60% confidence

• Nearly one in five women worldwide are now living with obesity, and the burden intensifies during the menopause years when hormonal changes drive weight gain, redistribute fat to the abdomen, and increase cardiometabolic risk

  60% confidence

• Menopause, associated weight gain and unwanted changes in cardiometabolic markers can significantly impact long-term health and well-being of women, yet they remain one of the most neglected areas in obesity research

  60% confidence

• By week 72 of the STEP UP trial, nearly half of women in all menopausal groups shifted from obesity BMI categories to overweight or normal weight BMI categories on semaglutide 7.2 mg

  60% confidence

Data points we hold from this source